Exelixis, Inc. (EXEL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

SA Transcripts158.92K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Exelixis, Inc. (EXEL) Barclays 28th Annual Global Healthcare Conference March 11, 2026 12:00 PM EDT Company Participants Andrew Peters - Senior Vice President of Strategy Conference Call Participants Etzer Darout - Barclays Bank PLC, Research Division Presentation Etzer DaroutBarclays Bank PLC, Research Division Hello again, everyone. I'm Etzer Darout, senior biotech analyst at Barclays. It's my pleasure to have Exelixis with us. With us today, we have Senior Vice President of Strategy and Investor Relations, Andrew Peters. Thank you so much for joining us. And I'm sure folks are familiar with the Exelixis story, but maybe it'd be helpful to maybe just start with some introductory remarks, and then we'll go into Q&A. Andrew PetersSenior Vice President of Strategy Sure. Thank you again for the invite. Always like being in Miami this time of year, even though the weather in California is also nice this week. As a reminder, we're going to be making some forward-looking statements today. So please see disclosures around relative risks in our business in our SEC filings. So Exelixis is a commercial oncology company, really built around our lead molecule, CABOMETYX, cabo which is a tyrosine kinase inhibitor that targets VEGF as well as a whole host of others, Met, Axl, MER, the TAM kinases, really kind of designed to be a best-in-class molecule across a wide range of indications. It's approved in kidney cancer, liver cancer, thyroid cancer and now neuroendocrine tumors. And so it's really kind of provided the foundation and a lot of the insights is to what we do at the company, both from a research and discovery perspective, but importantly from a strategic perspective as well. And I'm sure I'll get to that a little bit later. We did $2.123 billion in net product sales last year. We've guided